2016 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/07/16XBiotech Completes Enrollment in Global Phase III Study using Xilonix Monotherapy to Treat Advanced Colorectal CancerPrinter Friendly Version
12/06/16XBiotech Completes Enrollment in Global Phase I/II Study for its True Human™ Antibody Treatment for Serious Staphylococcus aureus InfectionsPrinter Friendly Version
11/17/16XBiotech Announces Research Collaboration with Renowned GastroenterologistPrinter Friendly Version
11/10/16XBiotech to Provide Third Quarter 2016 Business Update on November 15Printer Friendly Version
10/12/16XBiotech Announces Successful Completion of EMA GMP InspectionPrinter Friendly Version
10/11/16XBiotech Announces Dismissal of Class Action Lawsuit in TexasPrinter Friendly Version
08/22/16XBiotech Announces Grand Opening Date for New Commercial Manufacturing FacilityPrinter Friendly Version
08/10/16XBiotech to Provide Second Quarter 2016 Business Update on August 16Printer Friendly Version
07/22/16XBiotech Provides Update on Xilonix™ Phase III Programs in US and EUPrinter Friendly Version
07/02/16XBiotech Presents Pivotal Phase III Data Showing Xilonix(TM) Demonstrated Significant Clinical Response in Advanced Colorectal Cancer Patients Refractory to Further TreatmentPrinter Friendly Version
06/28/16XBiotech Signs Agreement With Megapharm To Market Xilonix™ In IsraelPrinter Friendly Version
06/08/16XBiotech Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Company's Extensive Product PortfolioPrinter Friendly Version
05/24/16XBiotech to Present Positive Preliminary Survival Data on Xilonix(TM) at the 18th European Society of Medical Oncology's World Congress on Gastrointestinal CancerPrinter Friendly Version
05/18/16XBiotech Provides First Quarter 2016 Corporate and Clinical UpdatePrinter Friendly Version
05/16/16XBiotech Names Industry Veteran Dawn McCollough to Head Clinical OperationsPrinter Friendly Version
05/11/16XBiotech to Provide First Quarter 2016 Business Update on May 18Printer Friendly Version
05/03/16XBiotech Appoints Amgen Veteran Scott Whitehurst as Chief Financial OfficerPrinter Friendly Version
04/19/16XBiotech to Present Pivotal Phase 3 Data on Xilonix(TM) at European Society of Medical Oncology's World Congress on Gastrointestinal CancerPrinter Friendly Version
04/04/16European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix(TM), XBiotech's True Human(TM) Therapeutic Antibody Treatment for Advanced Colorectal CancerPrinter Friendly Version
03/28/16XBiotech Advances to Phase II Portion of Clinical Study of Novel True Human™ Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureusPrinter Friendly Version
03/23/16XBiotech Announces European Medicines Agency (EMA) Validates Marketing Authorization Application (MAA) for Xilonix™ in the Treatment of Advanced Colorectal CancerPrinter Friendly Version
03/22/16XBiotech to Provide Fourth Quarter and Full Year 2015 Business updatePrinter Friendly Version
03/09/16XBiotech Enrolls Final Patient in Phase I Portion of Clinical Study of Novel True Human™ Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureusPrinter Friendly Version
03/08/16XBiotech Announces Submission of Marketing Authorization Application (MAA) for Candidate Colorectal Cancer Therapy to European Medicines Agency (EMA)Printer Friendly Version
03/04/16European Medicines Agency Grants Eligibility for Submission of XBiotech’s Marketing Authorization Application (MAA)Printer Friendly Version
03/02/16XBiotech to Deliver Presentation on Novel Study Design and Phase III Results From European Study on Xilonix(TM) During Meeting at the European ParliamentPrinter Friendly Version
02/18/16XBiotech to Present at 4th Annual Sachs Cancer BioPartnering & Investment ForumPrinter Friendly Version
02/11/16XBiotech Engages in Research for Heart Attack Antibody TherapyPrinter Friendly Version
01/21/16XBiotech to Attend and Present at the ASCO 2016 Gastrointestinal Cancers SymposiumPrinter Friendly Version
01/08/16XBiotech Reports Additional Positive Data From Phase III European Trial of Xilonix™ in Advanced Colorectal CancerPrinter Friendly Version
01/07/16XBiotech to Host Overview of Strategy and Findings for Its European Phase III Trial for Treatment of Colorectal Cancer With Xilonix™Printer Friendly Version
01/07/16XBiotech Advances to Final Dosing Cohort in Phase 1/2 Clinical Study of Novel True Human™ Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureusPrinter Friendly Version
01/06/16XBiotech Added to NASDAQ Biotechnology IndexPrinter Friendly Version